CD33 is expressed by acute myeloid leukemia (AML) cells in> 80% of patients but not by
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …

Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …

The anti-CD33 antibody, P67. 6, has been chosen to target the potently cytotoxic
calicheamicin antitumor antibiotics to acute myeloid leukemia (AML) due to the presence of …

Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted
immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH], a potent …

Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …

Antibody-targeted chemotherapy is a promising therapy in patients with acute myeloid
leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which …

The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …

Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …

The purpose of this study was to characterize the pharmacokinetics of gemtuzumab
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …

Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of
the humanized murine CD33 antibody (clone P67. 6) to which the calicheamicin-g1 …